down arrow

Jinling Pharmaceutical Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE0000010W5
  • SHE: 000919
CNY
6.42
-0.07 (-1.08%)

Sep 24

SHE

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Jinling Pharmaceutical Co., Ltd.

Why is Jinling Pharmaceutical Co., Ltd. ?

1
With ROE of 1.44%, it has a very attractive valuation with a 0.81 Price to Book Value
  • Over the past year, while the stock has generated a return of -11.33%, its profits have risen by 2087.3% ; the PEG ratio of the company is 0
  • At the current price, the company has a high dividend yield of 1.6
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Jinling Pharmaceutical Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Jinling Pharmaceutical Co., Ltd. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Jinling Pharmaceutical Co., Ltd.
-7.09%
-0.15
34.63%
China Shanghai Composite
0.9%
1.20
14.07%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
3.27%
EBIT Growth (5y)
-34.23%
EBIT to Interest (avg)
39.68
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
0.81
Tax Ratio
21.65%
Dividend Payout Ratio
115.34%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.89%
ROE (avg)
3.84%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
66
Industry P/E
Price to Book Value
0.94
EV to EBIT
111.80
EV to EBITDA
15.23
EV to Capital Employed
0.92
EV to Sales
0.73
PEG Ratio
0.03
Dividend Yield
2.80%
ROCE (Latest)
0.82%
ROE (Latest)
1.44%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

19What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY 432.56 MM

INTEREST COVERAGE RATIO(Q)

Highest at 6,066.45

RAW MATERIAL COST(Y)

Fallen by -19.99% (YoY

OPERATING PROFIT(Q)

Highest at CNY 74.83 MM

OPERATING PROFIT MARGIN(Q)

Highest at 9.17 %

PRE-TAX PROFIT(Q)

Highest at CNY 41.24 MM

NET PROFIT(Q)

Highest at CNY 28.2 MM

-4What is not working for the Company
NET SALES(9M)

At CNY 2,401.62 MM has Grown at -9.79%

DEBT-EQUITY RATIO (HY)

Highest at -44.58 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.7 times

Here's what is working for Jinling Pharmaceutical Co., Ltd.

Interest Coverage Ratio
Highest at 6,066.45
in the last five periods
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Pre-Tax Profit
At CNY 41.24 MM has Grown at 167.34%
over average net sales of the previous four periods of CNY 15.43 MM
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Operating Cash Flow
Highest at CNY 432.56 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Operating Profit
Highest at CNY 74.83 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (CNY MM)

Operating Profit Margin
Highest at 9.17 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at CNY 41.24 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit
Highest at CNY 28.2 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

Net Profit
At CNY 28.2 MM has Grown at 95.1%
over average net sales of the previous four periods of CNY 14.46 MM
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

Raw Material Cost
Fallen by -19.99% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Jinling Pharmaceutical Co., Ltd.

Net Sales
At CNY 2,401.62 MM has Grown at -9.79%
Year on Year (YoY)
MOJO Watch
Near term sales trend is negative

Net Sales (CNY MM)

Debt-Equity Ratio
Highest at -44.58 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio
Lowest at 2.7 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Footer loading